Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1629 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 |
filingDate |
2005-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd983c3ad78b6f678b6a785e4062b87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5089895471ce48e151412cbfd8869ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53b743e3f4de6a499fc7cfcddc3b88ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e62d9bac1102013cbe91ff146e2781aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44b95307b13f2e8ef106271aeddba021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f52dc77e7f738995a30d809849605a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_addf38185e3bb4b7b7a0aadaa9cde3ed |
publicationDate |
2009-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2009142404-A1 |
titleOfInvention |
Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
abstract |
A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. Exemplified low-solubility drugs are ziprasidone and sildenafil. Exemplified precipitation-inhibiting polymer is HPMCAS. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018111106-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11364203-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9757338-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022081310-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011148253-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9445998-B2 |
priorityDate |
2004-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |